Siemens Healthineers reported 8.1% core organic sales growth in its fiscal fourth quarter. Management set an outlook for 4%-5% core revenue growth and flat earnings in 2027. It also announced the timeline for the diagnostics separation.
Varian continues to grow at above-average levels, taking market share in new orders. Its product portfolio is materially broader than its key competitors'.
Bears
China remains a near-term drag for the entire industry, particularly diagnostics. Recovery in this market might take longer than expected, and growth isn't likely to return to the prior levels.
Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, and diagnostics. The imaging segment (56% of sales in fiscal 2025) includes magnetic resonance imaging, computed tomography, X-ray systems, and molecular imaging. The Varian business, now within Precision Therapies, (18% of sales) offers radiotherapy and other oncology solutions. The diagnostics segment (19%) includes in vitro diagnostics and point-of-care diagnostics. The advanced therapies (now part of precision therapy) segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. The Americas represents 44% of total sales, Europe, Middle East, and Africa 32%, and Asia-Pacific, including China (11%), the remainder.